Market Research Logo

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

Summary

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug - omalizumab - approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.

Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.

Scope

The respiratory disorders market is characterized by entrenched, commercially successful therapies.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?
  • What are the future prospects for the leading brands?
The pipeline contains a range of molecule types and molecular targets, with a growing presence of targeted therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • What are the commercial prospects for the most promising late-stage pipeline products?
Respiratory disorders clinical trials have an overall attrition rate of 89.1%.
  • What are the failure rates at individual phases of clinical development?
  • How do the key respiratory disorders compare in terms of clinical trial failure rate?
The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%.
  • How much of a role will pipeline product approvals play in market growth?
  • Are the large number of recently approved products expected to drive market growth?
  • Will generic competition have a significant impact on the market over the forecast period?
  • Which products face generic competition?
Big pharma holds a notable presence in the market.
  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the greatest growth in market share?
  • Which company will hold the largest market share in 2022?
  • How dependent are the key companies on this disease cluster for revenue?
  • Which companies rely heavily on this disease cluster for revenue?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in respiratory disorders.
  • Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
  • Analyze the respiratory disorders pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory disorder products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the respiratory disorder deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.


Cystic fibrosis therapies will push Vertex ahead of GSK in $46.6 billion respiratory market by 2022, says GBI Research

The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably from $28.1 billion in 2015 to $46.6 billion by 2022, at a compound annual growth rate (CAGR) of 7.5%, according to business intelligence provider GBI Research.

The company’s latest report states that although the patent expirations of the commercially successful Advair, Symbicort, Ventolin and Spiriva will allow generics to enter the market, the impact of these expirations will be offset by the approval of new products.

Yasser Mushtaq, Senior Analyst for GBI Research, explains: “Recently approved products in COPD include multiple long-acting beta-2 agonist/long-acting muscarinic antagonist (LAMA) fixed-dose combinations, some of which are forecast to generate over $1 billion by 2022, and include GlaxoSmithKline’s (GSK’s) Anoro, Novartis’s Ultibro and Boehringer Ingelheim’s Stiolto.“The approvals of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab) and Cinqair (reslizumab), marketed by GSK and Novartis, respectively, are also forecast to have a strong commercial impact on the market.”

Although GSK is currently the leading company in terms of revenue generated from respiratory disorder products, GBI Research expects Vertex, which specialises in the cystic fibrosis segment, to overtake GSK by 2022.

Mushtaq continues: “The emergence of transmembrane conductance regulator modulating therapies, which are considered disease-modifying therapies for cystic fibrosis, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact.“There are only two of these products on the market - Kalydeco and Orkambi - both of which were developed by Vertex. They are forecast to generate $2.8 billion and $6.8 billion, respectively, by 2022, driven by strong demand for disease-modifying therapies. Vertex also has a Phase III candidate of the same class, which is expected to achieve blockbuster status during the forecast period.

“These factors, combined with the limited or negative growth forecast for other key players in the market, including GSK, Boehringer Ingelheim and AstraZeneca, will allow Vertex to become the leading company in the respiratory disorders landscape in terms of revenue generated by 2022.”

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

  • Comments provided by Yasser Mushtaq, Seinor Analyst for GBI Research.
  • Information based on GBI Research’s report: Global Respiratory Drugs Market to 2022.
  • This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Substantial Unmet Needs Remain in Core Therapy Types
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline
2.3 Rich Pipeline Landscape with Numerous Investment Opportunities
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 GBI Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.1.1 Chronic and Neuropathic Pain
4.1.2 Disease Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment Options
4.2 Overview of Marketed Products for Pain
4.2.1 Analgesic Product Categories
4.2.2 Molecular Type Analysis
4.2.3 Current Unmet Needs
5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain
5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.4 First-in-Class and Established Pipeline Products by Pain Subtype
5.5 Table of All First-in-Class Pain Pipeline Products
6 Pain Pathophysiology and Innovation Alignment
6.1 The Complexity of Signaling Networks in the Central Nervous System
6.2 Matrix Assessment
7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Nerve Growth Factor and High Affinity Nerve Growth Factor Receptor
7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16
7.3 Pipeline Programs Targeting Bradykinin B1 Receptor
7.4 Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor
7.5 Pipeline Programs Targeting Purinoceptor 7
7.6 Pipeline Programs Targeting Metabotropic Glutamate Receptors 6 and 7
7.7 Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor
8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Pain Deals Landscape
8.3 Licensing Deals
8.3.1 Molecule Type
8.3.2 Mechanism of Action
8.4 Co-development Deals
8.4.1 Molecule Type
8.4.2 Mechanism of Action
8.5 List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement
9 Appendix
9.1 Abbreviations
9.2 References
9.3 Contact Us
9.4 Disclaimer
1.1 List of Tables
Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2016 11
Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age 25
Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age 26
Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults 27
Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016 28
Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016 29
Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016 29
Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016 31
Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016 33
Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016 35
Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2016 38
Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Spiriva, 2016 40
Table 13: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2016 42
Table 14: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2016 43
Table 15: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Flixotide, 2016 46
Table 16: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2016 47
Table 17: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2016 48
Table 18: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmozyme, 2016 50
Table 19: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2016 51
Table 20: Respiratory Disorders Therapeutics Market, Global, Approved Indications for TOBI, 2016 53
Table 21: Respiratory DIsorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016 78
Table 22: Respiratory Disorders Therapeutics Market, Global, Forecast Revenue by Company, 2016 94
Table 23: Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016 114
Table 24: Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016 121
Table 25: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Discovery, 2016 130
Table 26: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Preclinical, 2016 139
Table 27: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, IND/CTA filed/Phase 0, 2016 171
Table 28: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase I, 2016 172
Table 29: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase II, 2016 181
Table 30: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase III, 2016 191
Table 31: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Pre-registration, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report